ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.663,06
0,95%
S&P 500
5.187,67
0,00%
Dow Jones
39.056,39
0,00%
Euro vs US Dollar
1,07563
0,09%
Bitcoin
61.407,64
0,36%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Aura Biosciences Inc (AURA)

  7. Aura Biosciences Inc (AURA) News

AURA

Aura Biosciences (AURA)

Aura Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AURA
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202413h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AURAAura Biosciences Inc
09/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
09/05/202413h00GlobeNewswire Inc.Aura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
08/05/202413h00GlobeNewswire Inc.Aura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
27/03/202412h00Business WireAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
04/03/202423h35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
26/02/202413h00Business WireAura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
23/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
02/02/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
02/02/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
02/02/202422h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
24/01/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
24/01/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
24/01/202422h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
24/01/202422h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
08/01/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
08/01/202413h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
02/01/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
15/12/202322h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
07/12/202314h00Business WireAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
09/11/202323h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
09/11/202322h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
09/11/202322h05Business WireAura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
08/11/202313h00Business WireAura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
08/11/202300h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
08/11/202300h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
07/11/202322h55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AURAAura Biosciences Inc
07/11/202304h02Business WireAura Biosciences Announces Pricing of Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
06/11/202322h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
06/11/202322h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:AURA

Kürzlich von Ihnen besucht

USOTC
ADDYY
Adidas (QX)
DBI
TDXP
Tec DAX
TG
MBG
MercedesBenz
AMEX
XLV
Health Care Select Sector
NYSE
JPM
JP Morgan Chase
NASDAQ
NVDA
NVIDIA
COIN
SOLUSD
Solana
DBI
MDAX
MDAX
TG
LHA
Deutsche Lufthansa
CCOM
US500
US 500
COIN
ETHUSD
Ethereum
DBI
SDXP
SDAX
USOTC
BNPQY
BNP Paribas (QX)
USOTC
BASFY
BASF (QX)
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten